Paris (ots/PRNewswire) – – This cutting-edge technology helps radiologists interpret screening mammograms, enabling them to diagnose breast cancer earlier and more accurately.
Therapixel announced today that the MammoScreen (TM) has successfully received the CE mark. After this AI solution received approval from the US FDA in March 2020 for commercial distribution in the USA, it is now also available on the European market.
MammoScreen (TM) automatically analyzes screening mammograms and displays suspicious mammograms and lesions to the radiologist. Depending on the likelihood of maliciousness and the level of confidence in the algorithm, the software assigns a unique “MammoScreen Score (TM)” ranging from 1 to 10.
A clinical study was conducted in 2019 and in Radiology: AI Released, Showing Radiologists Assisted By MammoScreen (TM) Perform Better Than Without the Software.
In addition, MammoScreen (TM) helps increase the speed at which benign images are interpreted, giving doctors more time to focus on cases that require more attention.
The MammoScreen (TM) has already been installed in 14 hospitals and radiology practices in France for clinical evaluations and has sparked great enthusiasm among radiologists. Doctors find it to be an intuitive and easy-to-use tool that gives them confidence in their interpretation and prevents them from overlooking cancers.
Breast cancer is one of the most common and deadliest types of cancer in women worldwide, affecting 1 in 8 women in their lifetime. The earlier this disease is diagnosed, the more effective the treatment will be.
“We are proud to have received the CE mark. This brings us one step closer to our goal of reducing the burden of breast cancer worldwide by improving breast cancer screening,” said Pierre Fillard, Founder and Chief Scientific Officer of Therapixel.
“I am confident that MammoScreen (TM) will not only improve radiologist performance, it will also improve the patient experience by calming women faster,” said Matthieu Leclerc-Chalvet, CEO of Therapixel.
Information about Therapixel
Therapixel is a French company specializing in the development and marketing of AI-powered medical imaging software with the aim of bringing relevant information to healthcare professionals at the right time. As the winner of the Digital Mammography DREAM Challenge in 2017, the global competition for breast cancer detection with AI, Therapixel developed MammoScreen (TM), software that aids in the interpretation of screening mammograms. With MammoScreen (TM), even experienced radiologists can improve their performance, feel more confident in their judgment, and reassure women faster. For more information, see www.mammoscreen.com
Inquiries & contact:
Logo – mma.prnewswire.com/media/1418252/Therapixel_Logo.jpg